Matches in SemOpenAlex for { <https://semopenalex.org/work/W2332888891> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2332888891 abstract "Background Biological drugs are effective treatments for chronic plaque psoriasis. The doses tend to be reduced when the drug has demonstrated sustained effectiveness. Purpose The main objective was to assess the average cost per patient of each anti-TNF drug based on its prescribed doses. The secondary objective was two-fold: to estimate the annual costs per responder and the incremental cost. Material and methods A cross-sectional observational study was conducted from January to June 2014. Patients with psoriasis who had received biological treatment for at least six months were included. The effectiveness endpoint was the proportion of patients with at least 75% improvement in the psoriasis area-and-severity index (PASI75). Mean prescribed doses of each anti-TNF drug were calculated and translated into a percentage of the label doses. The average cost per patient for each drug was assessed with the mean prescribed doses (real costs, RC) and the theoretical costs (TC) were estimated based on the label doses of the drugs. The incremental cost (IC) was calculated by comparing the theoretical vs. real costs. For the purpose of calculating the annual costs, the real costs of six months of treatment were extrapolated. This study was performed from the pharmacoeconomic perspective of the hospital. Results We included 143 patients. Conclusion The average RC of each biological drug was lower than TC, except for infliximab. Both the annual RC and the IC of adalimumab were better than the other drugs, followed by etanercept and ustekinumab. Infliximab did not allow dose reduction. Reducing doses of biological treatments permits cost minimisation while maintaining clinical effectiveness. References and/or Acknowledgements No conflict of interest." @default.
- W2332888891 created "2016-06-24" @default.
- W2332888891 creator A5026941208 @default.
- W2332888891 creator A5038951985 @default.
- W2332888891 creator A5040853059 @default.
- W2332888891 creator A5040878823 @default.
- W2332888891 creator A5072093603 @default.
- W2332888891 creator A5074037141 @default.
- W2332888891 creator A5077788052 @default.
- W2332888891 date "2015-03-01" @default.
- W2332888891 modified "2023-09-27" @default.
- W2332888891 title "CP-142 Biological treatments for psoriasis: financial impact of dose modification: Abstract CP-142 Table 1" @default.
- W2332888891 doi "https://doi.org/10.1136/ejhpharm-2015-000639.136" @default.
- W2332888891 hasPublicationYear "2015" @default.
- W2332888891 type Work @default.
- W2332888891 sameAs 2332888891 @default.
- W2332888891 citedByCount "0" @default.
- W2332888891 crossrefType "journal-article" @default.
- W2332888891 hasAuthorship W2332888891A5026941208 @default.
- W2332888891 hasAuthorship W2332888891A5038951985 @default.
- W2332888891 hasAuthorship W2332888891A5040853059 @default.
- W2332888891 hasAuthorship W2332888891A5040878823 @default.
- W2332888891 hasAuthorship W2332888891A5072093603 @default.
- W2332888891 hasAuthorship W2332888891A5074037141 @default.
- W2332888891 hasAuthorship W2332888891A5077788052 @default.
- W2332888891 hasConcept C126322002 @default.
- W2332888891 hasConcept C16005928 @default.
- W2332888891 hasConcept C17991360 @default.
- W2332888891 hasConcept C23131810 @default.
- W2332888891 hasConcept C2777011040 @default.
- W2332888891 hasConcept C2777138892 @default.
- W2332888891 hasConcept C2777226972 @default.
- W2332888891 hasConcept C2778715236 @default.
- W2332888891 hasConcept C2778975655 @default.
- W2332888891 hasConcept C2780035454 @default.
- W2332888891 hasConcept C2780132546 @default.
- W2332888891 hasConcept C2780564577 @default.
- W2332888891 hasConcept C71924100 @default.
- W2332888891 hasConcept C98274493 @default.
- W2332888891 hasConceptScore W2332888891C126322002 @default.
- W2332888891 hasConceptScore W2332888891C16005928 @default.
- W2332888891 hasConceptScore W2332888891C17991360 @default.
- W2332888891 hasConceptScore W2332888891C23131810 @default.
- W2332888891 hasConceptScore W2332888891C2777011040 @default.
- W2332888891 hasConceptScore W2332888891C2777138892 @default.
- W2332888891 hasConceptScore W2332888891C2777226972 @default.
- W2332888891 hasConceptScore W2332888891C2778715236 @default.
- W2332888891 hasConceptScore W2332888891C2778975655 @default.
- W2332888891 hasConceptScore W2332888891C2780035454 @default.
- W2332888891 hasConceptScore W2332888891C2780132546 @default.
- W2332888891 hasConceptScore W2332888891C2780564577 @default.
- W2332888891 hasConceptScore W2332888891C71924100 @default.
- W2332888891 hasConceptScore W2332888891C98274493 @default.
- W2332888891 hasLocation W23328888911 @default.
- W2332888891 hasOpenAccess W2332888891 @default.
- W2332888891 hasPrimaryLocation W23328888911 @default.
- W2332888891 hasRelatedWork W1977487899 @default.
- W2332888891 hasRelatedWork W1996905829 @default.
- W2332888891 hasRelatedWork W2019219799 @default.
- W2332888891 hasRelatedWork W2092310057 @default.
- W2332888891 hasRelatedWork W2098411486 @default.
- W2332888891 hasRelatedWork W2111948020 @default.
- W2332888891 hasRelatedWork W2115474873 @default.
- W2332888891 hasRelatedWork W2149338618 @default.
- W2332888891 hasRelatedWork W2202946002 @default.
- W2332888891 hasRelatedWork W2293590890 @default.
- W2332888891 hasRelatedWork W2327382382 @default.
- W2332888891 hasRelatedWork W2412334351 @default.
- W2332888891 hasRelatedWork W2416288603 @default.
- W2332888891 hasRelatedWork W2745179561 @default.
- W2332888891 hasRelatedWork W2756408095 @default.
- W2332888891 hasRelatedWork W2774233423 @default.
- W2332888891 hasRelatedWork W2803541677 @default.
- W2332888891 hasRelatedWork W2911714458 @default.
- W2332888891 hasRelatedWork W3103233798 @default.
- W2332888891 hasRelatedWork W74056987 @default.
- W2332888891 isParatext "false" @default.
- W2332888891 isRetracted "false" @default.
- W2332888891 magId "2332888891" @default.
- W2332888891 workType "article" @default.